Vaxart Inc reports results for the quarter ended September 30 - Earnings Summary

Vaxart

14/11/2024 04:20

* Vaxart Inc  VXRT.OQ  reported a quarterly adjusted loss
of 6
cents​​ per share for the quarter ended September 30, higher
than the same quarter last year, when the company reported EPS
of -11 cents.  The mean expectation of three analysts for the
quarter was for a loss of 10 cents per share. Wall Street
expected results to range from -13 cents to -8 cents per share.
    * Revenue rose 134.8% to $4.93 million from a year ago;
analysts
expected $850.00 thousand. 
    * Vaxart Inc's reported EPS for the quarter was a loss of 6
cents​.
    * The company reported a quarterly loss of $14.08 million.
    * Vaxart Inc shares had fallen by 14.9% this quarter and
gained 26.1% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 9.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Vaxart Inc is
4.00 
This summary was machine generated from LSEG data November 14 at
04:20 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.10          -0.06          Beat
 Jun. 30 2024      -0.03          -0.09          Missed
 Mar. 31 2024      -0.14          -0.14          Met
 Dec. 31 2023      -0.14          -0.12          Beat